Neuland Laboratories Ltd

Neuland Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Neuland Laboratories Ltd

₹ 11,999 2.84%
04 Jul - close price
neulandlabs.com BSE: 524558 NSE: NEULANDLAB
About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Key Points

Business Segments
1. Prime APIs
This segment comprises ~15 mature large volume APIs in a highly competitive market. The key molecules in this primary revenue generating segment are Levetiracetam and Mirtazapine. [1]

Website BSE NSE
  • Market Cap ₹ 15,395 Cr.
  • Current Price ₹ 11,999
  • High / Low ₹ 18,100 / 7,575
  • Stock P/E 75.9
  • Book Value ₹ 1,188
  • Dividend Yield 0.10 %
  • ROCE 18.2 %
  • ROE 14.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 66.0% CAGR over last 5 years

Cons

  • Stock is trading at 10.1 times its book value
  • Earnings include an other income of Rs.96.9 Cr.
  • Promoter holding has decreased over last 3 years: -3.54%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty Smallcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
256 221 294 269 407 363 418 393 385 440 311 398 328
217 193 224 215 287 266 280 272 278 316 249 311 277
Operating Profit 39 29 69 54 120 97 137 121 107 123 62 87 51
OPM % 15% 13% 24% 20% 29% 27% 33% 31% 28% 28% 20% 22% 16%
1 1 0 1 8 2 3 2 5 25 4 60 7
Interest 3 3 3 3 4 2 4 4 4 3 1 2 2
Depreciation 12 13 13 13 13 14 15 15 16 16 16 16 17
Profit before tax 24 13 53 39 110 83 122 104 92 130 49 128 39
Tax % 10% 26% 28% 22% 23% 26% 27% 22% 27% 25% 34% 20% 29%
22 10 38 31 85 62 89 81 68 98 33 102 28
EPS in Rs 16.98 7.77 29.98 23.81 65.89 48.23 69.56 63.44 52.66 76.28 25.60 79.18 21.68
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
466 469 510 579 527 667 763 937 951 1,191 1,559 1,477
395 402 430 472 477 608 661 790 807 918 1,096 1,154
Operating Profit 71 67 80 106 51 58 102 147 144 273 463 323
OPM % 15% 14% 16% 18% 10% 9% 13% 16% 15% 23% 30% 22%
3 0 2 1 4 3 4 16 0 9 12 97
Interest 25 27 24 21 19 16 22 18 14 13 14 8
Depreciation 15 15 16 19 22 26 31 40 49 53 60 66
Profit before tax 35 25 42 67 14 20 53 105 82 216 401 346
Tax % 23% 36% 36% 30% 13% 19% 69% 23% 22% 24% 25% 25%
27 16 27 47 12 16 16 81 64 164 300 260
EPS in Rs 30.12 17.96 30.75 52.74 13.57 12.81 12.63 62.85 49.74 127.45 233.89 202.74
Dividend Payout % 9% 8% 7% 0% 0% 0% 16% 8% 10% 8% 6% 6%
Compounded Sales Growth
10 Years: 12%
5 Years: 14%
3 Years: 16%
TTM: -5%
Compounded Profit Growth
10 Years: 29%
5 Years: 66%
3 Years: 46%
TTM: -33%
Stock Price CAGR
10 Years: 40%
5 Years: 87%
3 Years: 112%
1 Year: 54%
Return on Equity
10 Years: 12%
5 Years: 16%
3 Years: 19%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 8 9 9 9 9 13 13 13 13 13 13 13
Reserves 116 152 178 537 549 686 697 774 828 981 1,270 1,512
190 188 182 192 319 231 264 182 241 128 95 157
169 162 155 148 194 200 257 356 302 457 454 498
Total Liabilities 483 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,833 2,180
131 123 139 466 475 542 653 716 767 758 824 958
CWIP 35 41 40 20 126 104 24 17 20 41 46 45
Investments 7 7 7 8 8 8 8 7 4 1 1 109
311 340 337 393 463 476 547 585 592 781 962 1,068
Total Assets 483 512 524 886 1,071 1,130 1,231 1,325 1,383 1,580 1,833 2,180

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
49 13 45 39 11 70 57 189 60 237 261 317
-10 -14 -20 -42 -116 -77 -49 -84 -95 -61 -150 -298
-39 1 -24 -0 105 12 -5 -114 38 -136 -69 25
Net Cash Flow -0 0 1 -4 -0 5 3 -9 3 40 42 44

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 93 100 85 114 134 90 91 85 90 111 87 78
Inventory Days 138 170 182 186 266 191 209 205 227 211 220 240
Days Payable 139 167 121 118 189 118 110 126 100 129 121 157
Cash Conversion Cycle 92 103 147 182 211 162 190 164 216 193 187 161
Working Capital Days 89 124 115 139 176 126 131 93 124 96 98 114
ROCE % 19% 16% 18% 16% 4% 4% 8% 11% 10% 21% 33% 18%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
36.22% 36.22% 36.14% 36.14% 36.03% 35.97% 32.80% 32.74% 32.72% 32.64% 32.68% 32.67%
17.39% 17.68% 17.70% 18.14% 20.19% 21.57% 22.69% 24.43% 25.72% 26.46% 23.86% 22.12%
6.45% 6.57% 6.54% 7.10% 6.76% 6.99% 6.02% 6.54% 6.39% 6.38% 9.09% 10.97%
0.00% 0.44% 0.46% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40%
39.94% 39.07% 39.15% 38.22% 36.62% 35.08% 38.10% 35.88% 34.77% 34.12% 33.96% 33.85%
No. of Shareholders 31,97630,60029,66926,94825,22326,82427,72328,61629,07734,56739,31539,333

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls